432 related articles for article (PubMed ID: 28244643)
21. Detection of anti-asparaginase antibodies during therapy with E.coli asparaginase in children with newly diagnosed acute lymphoblastic leukemia and lymphoma.
Ebeid EN; Kamel MM; Ali BA
J Egypt Natl Canc Inst; 2008 Jun; 20(2):127-33. PubMed ID: 20029468
[TBL] [Abstract][Full Text] [Related]
22. A prospective study on drug monitoring of PEGasparaginase and Erwinia asparaginase and asparaginase antibodies in pediatric acute lymphoblastic leukemia.
Tong WH; Pieters R; Kaspers GJ; te Loo DM; Bierings MB; van den Bos C; Kollen WJ; Hop WC; Lanvers-Kaminsky C; Relling MV; Tissing WJ; van der Sluis IM
Blood; 2014 Mar; 123(13):2026-33. PubMed ID: 24449211
[TBL] [Abstract][Full Text] [Related]
23. Comparison of Escherichia coli-asparaginase with Erwinia-asparaginase in the treatment of childhood lymphoid malignancies: results of a randomized European Organisation for Research and Treatment of Cancer-Children's Leukemia Group phase 3 trial.
Duval M; Suciu S; Ferster A; Rialland X; Nelken B; Lutz P; Benoit Y; Robert A; Manel AM; Vilmer E; Otten J; Philippe N
Blood; 2002 Apr; 99(8):2734-9. PubMed ID: 11929760
[TBL] [Abstract][Full Text] [Related]
24. Asparaginase pharmacodynamics differ by formulation among children with newly diagnosed acute lymphoblastic leukemia.
Hak LJ; Relling MV; Cheng C; Pei D; Wang B; Sandlund JT; Rubnitz J; Pui CH
Leukemia; 2004 Jun; 18(6):1072-7. PubMed ID: 15057247
[TBL] [Abstract][Full Text] [Related]
25. Pharmacokinetics and drug monitoring of L-asparaginase treatment.
Boos J
Int J Clin Pharmacol Ther; 1997 Mar; 35(3):96-8. PubMed ID: 9088996
[TBL] [Abstract][Full Text] [Related]
26. Population pharmacokinetics of intravenous Erwinia asparaginase in pediatric acute lymphoblastic leukemia patients.
Sassen SD; Mathôt RA; Pieters R; Kloos RQ; de Haas V; Kaspers GJ; van den Bos C; Tissing WJ; Te Loo M; Bierings MB; Kollen WJ; Zwaan CM; van der Sluis IM
Haematologica; 2017 Mar; 102(3):552-561. PubMed ID: 28250007
[TBL] [Abstract][Full Text] [Related]
27. Allergic reactions to Erwinia asparaginase in children with acute lymphoblastic leukemia who had previous allergic reactions to Escherichia coli asparaginase.
Billett AL; Carls A; Gelber RD; Sallan SE
Cancer; 1992 Jul; 70(1):201-6. PubMed ID: 1606543
[TBL] [Abstract][Full Text] [Related]
28. Prolonged first-line PEG-asparaginase treatment in pediatric acute lymphoblastic leukemia in the NOPHO ALL2008 protocol-Pharmacokinetics and antibody formation.
Tram Henriksen L; Gottschalk Højfeldt S; Schmiegelow K; Frandsen TL; Skov Wehner P; Schrøder H; Klug Albertsen B;
Pediatr Blood Cancer; 2017 Dec; 64(12):. PubMed ID: 28660740
[TBL] [Abstract][Full Text] [Related]
29. Erwinia asparaginase in pediatric acute lymphoblastic leukemia.
Salzer W; Seibel N; Smith M
Expert Opin Biol Ther; 2012 Oct; 12(10):1407-14. PubMed ID: 22946493
[TBL] [Abstract][Full Text] [Related]
30. L-asparagine depletion and L-asparaginase activity in children with acute lymphoblastic leukemia receiving i.m. or i.v. Erwinia C. or E. coli L-asparaginase as first exposure.
Rizzari C; Zucchetti M; Conter V; Diomede L; Bruno A; Gavazzi L; Paganini M; Sparano P; Lo Nigro L; Aricò M; Milani M; D'Incalci M
Ann Oncol; 2000 Feb; 11(2):189-93. PubMed ID: 10761754
[TBL] [Abstract][Full Text] [Related]
31. Individualized Asparaginase Dosing in Childhood Acute Lymphoblastic Leukemia.
Kloos RQH; Pieters R; Jumelet FMV; de Groot-Kruseman HA; van den Bos C; van der Sluis IM
J Clin Oncol; 2020 Mar; 38(7):715-724. PubMed ID: 31922920
[TBL] [Abstract][Full Text] [Related]
32. l-asparaginase loaded red blood cells in refractory or relapsing acute lymphoblastic leukaemia in children and adults: results of the GRASPALL 2005-01 randomized trial.
Domenech C; Thomas X; Chabaud S; Baruchel A; Gueyffier F; Mazingue F; Auvrignon A; Corm S; Dombret H; Chevallier P; Galambrun C; Huguet F; Legrand F; Mechinaud F; Vey N; Philip I; Liens D; Godfrin Y; Rigal D; Bertrand Y
Br J Haematol; 2011 Apr; 153(1):58-65. PubMed ID: 21332712
[TBL] [Abstract][Full Text] [Related]
33. Effect of glucocorticoids, E. coli- and Erwinia L-asparaginase on hemostatic proteins in children with acute lymphoblastic leukemia.
Mall V; Thomas KB; Sauter S; Niemeyer CM; Sutor AH
Klin Padiatr; 1999; 211(4):205-10. PubMed ID: 10472551
[TBL] [Abstract][Full Text] [Related]
34. L-Asparagine depletion in plasma and cerebro-spinal fluid of children with acute lymphoblastic leukemia during subsequent exposures to Erwinia L-asparaginase.
Gentili D; Conter V; Rizzari C; Tschuemperlin B; Zucchetti M; Orlandoni D; D'Incalci M; Masera G
Ann Oncol; 1996 Sep; 7(7):725-30. PubMed ID: 8905031
[TBL] [Abstract][Full Text] [Related]
35. Pharmacokinetic and pharmacodynamic properties of calaspargase pegol Escherichia coli L-asparaginase in the treatment of patients with acute lymphoblastic leukemia: results from Children's Oncology Group Study AALL07P4.
Angiolillo AL; Schore RJ; Devidas M; Borowitz MJ; Carroll AJ; Gastier-Foster JM; Heerema NA; Keilani T; Lane AR; Loh ML; Reaman GH; Adamson PC; Wood B; Wood C; Zheng HW; Raetz EA; Winick NJ; Carroll WL; Hunger SP
J Clin Oncol; 2014 Dec; 32(34):3874-82. PubMed ID: 25348002
[TBL] [Abstract][Full Text] [Related]
36. Pharmacokinetics of Erwinia asparaginase after intravenous and intramuscular administration.
Albertsen BK; Jakobsen P; Schrøder H; Schmiegelow K; Carlsen NT
Cancer Chemother Pharmacol; 2001 Jul; 48(1):77-82. PubMed ID: 11488528
[TBL] [Abstract][Full Text] [Related]
37. Minimal residual disease (MRD) measurement as a tool to compare the efficacy of chemotherapeutic drug regimens using Escherichia Coli-asparaginase or Erwinia-asparaginase in childhood acute lymphoblastic leukemia (ALL).
Kwok CS; Kham SK; Ariffin H; Lin HP; Quah TC; Yeoh AE
Pediatr Blood Cancer; 2006 Sep; 47(3):299-304. PubMed ID: 16302217
[TBL] [Abstract][Full Text] [Related]
38. A Randomized Phase I Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Recombinant Erwinia Asparaginase (JZP-458) in Healthy Adult Volunteers.
Lin T; Hernandez-Illas M; Rey A; Jenkins J; Chandula R; Silverman JA; Choi MR
Clin Transl Sci; 2021 May; 14(3):870-879. PubMed ID: 33278328
[TBL] [Abstract][Full Text] [Related]
39. Plasma asparaginase activity and asparagine depletion in acute lymphoblastic leukemia patients treated with pegaspargase on Children's Oncology Group AALL07P4
Schore RJ; Devidas M; Bleyer A; Reaman GH; Winick N; Loh ML; Raetz EA; Carroll WL; Hunger SP; Angiolillo AL
Leuk Lymphoma; 2019 Jul; 60(7):1740-1748. PubMed ID: 30626253
[TBL] [Abstract][Full Text] [Related]
40. Anti-Erwinia asparaginase antibodies during treatment of childhood acute lymphoblastic leukemia and their relationship to outcome: a case-control study.
Klug Albertsen B; Schmiegelow K; Schrøder H; Carlsen NT; Rosthøj S; Avramis VI; Jakobsen P
Cancer Chemother Pharmacol; 2002 Aug; 50(2):117-20. PubMed ID: 12172975
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]